The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC).
Payal Deepak Shah
No relevant relationships to disclose
Shanu Modi
Research Funding - Novartis
Farrah Mikhail Datko
No relevant relationships to disclose
Mary Ellen Moynahan
No relevant relationships to disclose
Stephen Zamora
No relevant relationships to disclose
Gabriella D'Andrea
No relevant relationships to disclose
Diana Lake
No relevant relationships to disclose
Shari Beth Goldfarb
No relevant relationships to disclose
Sujata Patil
No relevant relationships to disclose
Sharat Singh
Employment or Leadership Position - Prometheus
Emma J. Langley
Employment or Leadership Position - Prometheus
Phillip Sangwook Kim
Employment or Leadership Position - Prometheus
Anne M. Covey
No relevant relationships to disclose
Betty Ann Caravella
No relevant relationships to disclose
Michael F. Berger
No relevant relationships to disclose
Mario E. Lacouture
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Clifford A. Hudis
No relevant relationships to disclose
Jose Baselga
Consultant or Advisory Role - Novartis
Sarat Chandarlapaty
No relevant relationships to disclose
Maura N. Dickler
Research Funding - Novartis